Your Article Summary
Approval of Partial Change of API Manufacturing Method and Pharmaceutical Formulation of the Recombinant Human Erythropoietin "Epogin Injection"
Chugai Pharmaceutical Co., 06/17/09
Chugai Pharmaceutical Co., Ltd. announced that the company has acquired the approval for the partial change of the API manufacturing method and the pharmaceutical formulation of a recombinant human erythropoietin from the Japanese Ministry of Health, Labour and Welfare on April.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor


See Latest Articles


